DLK1 and neoplasm: We demonstrated the long-lasting anti-tumor efficacy of the afucosylated humanized anti-DLK1 antibody CBA-1205 as a single agent and in combination treatment with lenvatinib in two liver cancer cell xenograft mouse models.